Impact of CYP2C9 Polymorphisms on the Vulnerability to Pharmacokinetic Drug–drug Interactions During Acenocoumarol Treatment

• Ageno W , GallusAS, WittkowskyA et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis (9th Edition): American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2) , e44S–e88S (2012).
   PubMed Web of Science ®Google Scholar
• Holbrook A , SchulmanS, WittDM et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, (9th Edition): American College of chest physicians evidence-based clinical practice guidelines. Chest 141(Suppl. 2) , e152S–e184S (2012).
   PubMed Web of Science ®Google Scholar
• Palareti G , LealiN, CoccheriS et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 348(9025) , 423–428 (1996).
   PubMed Web of Science ®Google Scholar
• Ufer M . Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin. Pharmacokinet.44(12) , 1227–1246 (2005).
   PubMed Web of Science ®Google Scholar
• Thijssen HH , FlinoisJP, BeaunePH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab. Dispos.28(11) , 1284–1290 (2000).
   PubMed Web of Science ®Google Scholar
• Penning-Van Beest FJ , van Meegen E, Rosendaal FR, Stricker BH. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb. Haemostas.86(2) , 569–574 (2001).
   PubMed Web of Science ®Google Scholar
• Hylek EM , ReganS, GoAS, HughesRA, SingerDE, SkatesSJ. Clinical predictors of prolonged delay in return of the International Normalized Ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann. Intern. Med.135(6) , 393–400 (2001).
   PubMed Web of Science ®Google Scholar
• Stehle S , KirchheinerJ, LazarA, FuhrU. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin. Pharmacokinet.47(9) , 565–594 (2008).
   PubMed Web of Science ®Google Scholar
• Gong IY , TironaRG, SchwarzUI et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118(11) , 3163–3171 (2011).
   PubMed Web of Science ®Google Scholar
• Wadelius M , ChenLY, LindhJD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4) , 784–792 (2009).
   PubMed Web of Science ®Google Scholar
• Aithal GP , DayCP, KestevenPJ, DalyAK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet353(9154) , 717–719 (1999).
   PubMed Web of Science ®Google Scholar
• Higashi MK , VeenstraDL, KondoLM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13) , 1690–1698 (2002).
   PubMed Web of Science ®Google Scholar
• Cadamuro J , DieplingerB, FelderT et al. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur. J. Clin. Pharmacol. 66(3) , 253–260 (2010).
   PubMed Web of Science ®Google Scholar
• Schalekamp T , BrasseBP, RoijersJF et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin. Pharmacol. Ther.80(1) , 13–22 (2006).
   PubMed Web of Science ®Google Scholar
• Visser LE , van Vliet M, van Schaik RH et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics14(1) , 27–33 (2004).
   PubMedGoogle Scholar
• Lindh JD , HolmL, DahlML, AlfredssonL, RaneA. Incidence and predictors of severe bleeding during warfarin treatment. J. Thromb. Thrombolysis25(2) , 151–159 (2008).
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJ , KoerselmanJ, HeringsRM. Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. Pharm. World Sci.29(6) , 671–675 (2007).
   PubMedGoogle Scholar
• Gasse C , HollowellJ, MeierCR, HaefeliWE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb. Haemost.94(3) , 537–543 (2005).
   PubMed Web of Science ®Google Scholar
• Andersson ML , EliassonE, LindhJD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics13(7) , 757–762 (2012).
   PubMed Web of Science ®Google Scholar
• Uno T , SugimotoK, SugawaraK, TateishiT. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther. Drug Monit.30(3) , 276–281 (2008).
   PubMed Web of Science ®Google Scholar
• Miura M , TadaH, Yasui-FurukoriN et al. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br. J. Clin. Pharmacol. 60(1) , 61–68 (2005).
   PubMed Web of Science ®Google Scholar
• Aquilante CL , KosmiskiLA, BourneDW et al. Impact of the CYP2C8*3 polymorphism on the drug–drug interaction between gemfibrozil and pioglitazone. Br. J. Clin. Pharmacol. 75(1) , 217–226 (2013).
   PubMed Web of Science ®Google Scholar
• Rodriguez S , GauntTR, DayIN. Hardy–Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol.169(4) , 505–514 (2009).
   PubMed Web of Science ®Google Scholar
• Schalekamp T , KlungelOH, SouvereinPC, de Boer A. Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb. Haemost.100(6) , 1076–1083 (2008).
   PubMed Web of Science ®Google Scholar
• Obreli-Neto PR , NobiliA, de Oliveira Baldoni A et al. Adverse drug reactions caused by drug–drug interactions in elderly outpatients: a prospective cohort study. Eur. J. Clin. Pharmacol.68(12) , 1667–1676 (2012).
   PubMed Web of Science ®Google Scholar
• Hauta-Aho M , TirkkonenT, VahlbergT, LaineK. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann. Med.41(8) , 619–628 (2009).
   PubMed Web of Science ®Google Scholar
• Holbrook AM , PereiraJA, LabirisR et al. Systematic overview of warfarin and its drug and food interactions. Arch. Inter. Med. 165(10) , 1095–1106 (2005).
   PubMed Web of Science ®Google Scholar
• Gschwind L , RollasonV, LovisC et al. Identification and weighting of the most critical “real-life” drug–drug interactions with acenocoumarol in a tertiary care hospital. Eur. J. Clin. Pharmacol. 69(3) , 617–627 (2013).
   PubMed Web of Science ®Google Scholar
• Schalekamp T , van Geest-Daalderop JH, de Vries-Goldschmeding H, Conemans J, Bernsen MJMJ, de Boer A. Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin. Pharmacol. Ther.75(5) , 394–402 (2004).
   PubMed Web of Science ®Google Scholar
• Visser LE , van Schaik RH, van Vliet M et al. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin. Pharmacol. Ther.77(6) , 479–485 (2005).
   PubMed Web of Science ®Google Scholar
• Beinema MJ , de Jong PH, Salden HJ, van Wijnen M, van der Meer J, Brouwers JR. The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery. Mol. Diagn. Ther.11(2) , 123–128 (2007).
   PubMed Web of Science ®Google Scholar
• van Dijk KN , PlatAW, van Dijk AA et al. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype. Thromb. Haemost.91(1) , 95–101 (2004).
   PubMed Web of Science ®Google Scholar
• Saraeva RB , PaskalevaID, DonchevaE, EapCB, GanevVS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J. Clin. Pharm. Ther.32(6) , 641–649 (2007).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Pharmacogenetics of Acenocoumarol. http://clinicaltrials.gov/ct2/show/NCT01492777
   Google Scholar
• Table of substrates, inhibitors and inducers of Cytochrome P450. www.pharmacoclin.ch/_library/pdf/cytp450pgp.pdf (Accessed 17June2012)
   Google Scholar
• Algorithm for warfarin dosing. www.warfarindosing.org (Accessed 20June2012)
   Google Scholar